[1]
|
H. Covington, “Use of Propofol for Sedation in the ICV,” Critical Care Nursing, Vol. 18, No. 5, 1998, pp. 34-39.
|
[2]
|
R. D. Miller, “Local Anesthetics: Anesthesia,” In: R. D. Miller, Ed., Local Anesthetics, Churchill Livingstone, New York, Vol. 5, 2000, pp. 491-521.
|
[3]
|
O. Eriksson, P. Pollesello and N. E. Seris, “Inhibition of Lipid Peroxidation in Isolated Rat Liver Mitochondria by the General Anesthetic Propofol,” Biochemical Pharmacology, Vol. 44, No. 2, 1992, pp. 391-393.
|
[4]
|
P. G. Murphy, D. S. Myers, M. J. Davies, N. R. Webster and J. G. Jones, “The Antioxidant Potential of Propofol,” British Journal of Anesthesia, Vol. 68, No. 6, 1992, pp. 613-618.
|
[5]
|
M. Tsuchiya, A. Asada, K. Maeda, Y. Ueda, E. F. Sato, M. Shindo and M. Inove, “Propofol versus Medazolam Regarding their Antioxidant Activities,” American Journal of Respiratory and Critical Care Medicine, Vol. 163, No. 1, 2001, pp. 26-31.
|
[6]
|
H. C. Hemming and A. I. Adamo, “Effects of Halothane and Propofol on Purified Brain Protein Kinase C Activation,” Anesthesiology, Vol. 81, No. 1, 1994, pp. 147-155.
|
[7]
|
N. Kanaya, B. Gable, P. A. Murray and D. S. Damron, “Propofol Increases Phosphorylation of Troponin 1 and Myosin Light Chain via Protein Kinase C Activation in Cardiomyocytes,” Anesthesiology, Vol. 98, No. 6, 2003, pp. 1363-1371.
|
[8]
|
M. Horibe, I. Kondo, D. S. Damron and P. A. Murray, “Propofol Attenuates Capacitatine Calcium Entry in Pul- monary Artery Smooth Muscle Cells,” Anesthesiology, Vol. 95, No. 3, 2001, pp. 681-688.
|
[9]
|
N. Kanaya, P. A. Murray and D. S. Damron, “Propofol Increases Ca2+ Sensitivity and Intracellular pH via Activation of Na+ -H+ Exchange in Rat Ventricular Myocytes,” Anesthesiology, Vol. 94, No. 6, 2001, pp. 1096- 1104.
|
[10]
|
Y. Shin, S. Urano and T. Endo, “Antioxidant Property of Propofol and Related Monomeric and Dimeric Compounds,” Chemical and Pharmaceutical Bulletin, Vol. 53, No. 3, 2005, pp. 344-346.
|
[11]
|
P. E. Marik, “Propofol Therapeutic Indications and Side- Effects,” Current Pharmaceutical Design, Vol. 10, No. 29, 2004, pp. 3639-3649.
|
[12]
|
V. Ioanna, X. Theodoros, K. Eleni, P. Despoina, K. Chris, K. Athanasius and P. Lila, “Propofol: A Review of its Non-Anesthetic Effects,” European Journal of Pharmacology, Vol. 605, No. 1-3, 2009, pp. 1-8.
|
[13]
|
T. Mammoto, M. Mukai, A. Mammoto, Y. Yamanaka, Y. Hayashi, T. Mashimo, Y. Kishi and H. Nakamura, “Intravenous Anesthetic, Propofol Inhibits Invasion of Cancer Cells,” Cancer Letter, Vol. 184, No. 2, 2002, pp. 165- 170.
|
[14]
|
K. Atsuko, I. Takefumi and S. Koh, “Enhancement of Anti-Tumor Immunity after Propofol Treatment in Mice,” Immuno Pharmacology and Immunotoxicology, Vol. 29, No. 3-4, 2004, pp. 477-486.
|
[15]
|
R. A. Siddiqui, M. Zerouga, M. Wu, A. Castillo, K. Harvey, G. P. Zaloga and W. Stillwell, “Anti-Cancer Properties of Propofol-Docosahexaenoate and Propofoleicosa- pentaenoate on Breast Cancer Cells,” Breast Cancer Research, Vol. 7, No. 5, 2005, pp. 645-654.
|
[16]
|
K. A. Harvey, Z. Xu, P. Whitley, V. J. Davisson and R. A. Siddiqui, “Characterization of Anti-Cancer Properties of 2,6-Diisopropylphenoldocosahexaenoate and Analogues in Breast Cancer Cells,” Bioorganic and Medicinal Che- mistry, Vol. 18, No. 5, 2010, pp. 1866-1874.
|
[17]
|
J. A. Monendez, S. Ropero, R. Lupu and R. Colomer, “n-6 PUFA γ-Linolenic Acid (18: 3n-6) Enhances Docetaxel (Taxotere) Cytotoxicity in Human Breast Carcinoma Expression,” Oncology Reports, Vol. 11, No. 6, 2004, pp. 1241-1252.
|
[18]
|
M. P. Moyer, W. E. Hardman and I. Canceron, “Accelerated Action Fatty Acid (AAFA) Promotes Health of Normal Tissues and Minimizes the Toxic Side Effects of Chemotherapy,” U.S. Patent, 102907, 2002.
|
[19]
|
W. E. Hardman, I. L. Cameron and M. P. Moyer, “Fatty Acids to Minimize Cancer Therapy Side Effects,” PCT International, WO-US16666 0722, 1999.
|
[20]
|
S. C. Larsson, M. Kumlin, M. Ingelman-Sundberg and A. Wolk, “Dietary Longchain n-3 Fatty Acids for the Prevention of Cancer: A Review of Potential Mechanisms,” American Journal of Clinical Nutrition, Vol. 79, No. 6, 2004, pp. 935-945.
|
[21]
|
K. A. Conklin, “Dietary PUFA: Impact on Cancer Chemotherapy and Radiation,” Alternative Medicine Review: A Journal of Clinical Therapeutic, Vol. 7, No. 1, 2002, pp. 4-21.
|
[22]
|
P. Bougnoux, “n-3 PUFAs and Cancer,” Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 2, No. 2, 1999, pp. 121-126.
|
[23]
|
R. Berge, “Fatty Acid Analogues for the Treatment of Cancer,” PCT International, WO-NO301 20010713, 2001.
|
[24]
|
S. Pawar and S. Chattopadhyay, “10-Undecenoic Acid an Inexpensive Source for the Synthesis of the Pheromones of Cotton Pests, Peach Tree Borer and Cherry Tree Borer,” Molecules, Vol. 2, No. 6, 1997, pp. 87-90.
|
[25]
|
L. Shapiro and S. Rothman, “Undecylenic Acid in the Treatment of Dermatomycoses,” Archives of Dermatology and Syphilology, Vol. 52, No. 3, 1945, pp. 166-171.
|
[26]
|
N. Mc Lain, R. Ascanio and C. Baker, “Undecylenic Acid Inhibits Morphogenesis of Candida Albicans,” Antimicrobial Agents and Chemotherapy, Vol. 44, No. 10, 2000, pp. 2873-2875.
|
[27]
|
L. P. Ereaux and G. E. Craig, “Undecylenic Acid in Psoriasis,” Canadian Medical Association Journal, Vol. 61, No. 4, 1949, pp. 361-364.
|
[28]
|
N. Bourne, J. Ireland, L. R. Stanberry and D. I. Bemstein, “Effect of Undecylenic Acid as a Topical Microbicide against Geniotal Herpes Infection in Mice and Guinea Pigs,” Antiviral Research, Vol. 40, No. 3, 1999, pp. 139- 144.
|
[29]
|
S. D. Shafran, S. L. Sacks and F. Y. Aoki, “Topical Undecylenic Acid for Herpes Simplex Labiatus: A Multicenter, Placebo-Controlled Trial,” Journal of Infectious Diseases Infect Diseases, Vol. 176, No. 1, 1997, pp. 78-83.
|
[30]
|
V. P. M. Rahman, S. Mukhtar, W. H. Ansari and G. Lemiere, “Synthesis, Stereochemistry and Biological Activity of Some Novel Long Chain Substituted Thiazolidin- 4-Ones and Thiazan-4-One from 10-Undecenoic Acid Hydrazide,” European Journal of Medicinal Chemistry, Vol. 40, No. 4, 2005, pp. 173-184.
|
[31]
|
T. Yutaka, K. Masaru, R. Takao, Y. Shusaku and Y. Kenji, “Enzymatic Synthesis of Arbutin Undecylenic Acid Ester and its Inhibitory Effect on Melanin Synthesis,” Bioorganic and Medicinal Chemistry Letters, Vol. 17, No. 15, 2007, pp. 894-960.
|
[32]
|
J. Mustafa, S. I. Khan, G. Ma, L. A. Walker and I. A. Khan, “Synthesis, Spectroscopic and Biological Studies of Novel Estolides Derived from Anti-Tumor Active 4-O-Podophyllotoximyl 12-Hydroxyl Octadec-Z-9 Eno- ate,” Lipids, Vol. 39, No. 6, 2005, pp. 659-666.
|
[33]
|
P. R. Roper and B. Drewinko, “Comparision of in Vitro Methods to Determine Drug Induced Cell Lethality,” Cancer Research, Vol. 36, No. 7, 1976, pp. 2182-2188.
|
[34]
|
K. J. Tronstad, K. Berge, R. K. Berge and O. Bruserud, “Modified Fatty Acids and their Possible Therapeutic Targets in Malignant Diseases,” Expert Opinion on Therapeutic Targets, Vol. 7, No. 5, 2003, pp. 663-677.
|
[35]
|
J. Mustafa, S. I. Khan, G. Ma, L. A. Walker and I. A. Khan, “Synthesis and Anticancer Activities of FA Analogs of Podophyllotoxin,” Lipids, Vol. 39, No. 2, 2004, pp. 167-172.
|